Inhibitor Therapeutics, Inc. (INTI)
USD 0.06
(20.0%)
USD 0.06
(20.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.02 Million USD | -125.0% |
| 2022 | 12.1 Million USD | 3962.02% |
| 2021 | -313.46 Thousand USD | 70.34% |
| 2020 | -1.05 Million USD | 61.13% |
| 2019 | -2.71 Million USD | 40.25% |
| 2018 | -4.55 Million USD | 10.8% |
| 2017 | -5.1 Million USD | 27.13% |
| 2016 | -7 Million USD | -77.24% |
| 2015 | -3.94 Million USD | 0.65% |
| 2014 | -3.97 Million USD | -116.63% |
| 2013 | -1.83 Million USD | -1084.65% |
| 2012 | 186.36 Thousand USD | 181.78% |
| 2011 | -227.88 Thousand USD | 77.31% |
| 2010 | -1 Million USD | 57.45% |
| 2009 | -2.36 Million USD | 76.07% |
| 2008 | -9.86 Million USD | -257.59% |
| 2007 | -2.75 Million USD | -139.28% |
| 2006 | -1.15 Million USD | -1556.78% |
| 2005 | 79.12 Thousand USD | 121.53% |
| 2004 | -367.54 Thousand USD | -356.01% |
| 2003 | -80.6 Thousand USD | 87.12% |
| 2002 | -625.72 Thousand USD | 62.6% |
| 2001 | -1.67 Million USD | -81.47% |
| 2000 | -921.91 Thousand USD | 55.91% |
| 1999 | -2.09 Million USD | 0.42% |
| 1998 | -2.1 Million USD | -75.0% |
| 1997 | -1.2 Million USD | -1300.0% |
| 1996 | 100 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -501.68 Thousand USD | 26.73% |
| 2024 Q1 | -684.71 Thousand USD | 41.34% |
| 2023 Q1 | -449.46 Thousand USD | -101.78% |
| 2023 Q3 | -664.76 Thousand USD | -1.56% |
| 2023 FY | -3.02 Million USD | -125.0% |
| 2023 Q4 | -1.16 Million USD | -75.59% |
| 2023 Q2 | -654.52 Thousand USD | -45.62% |
| 2022 FY | 12.1 Million USD | 3962.02% |
| 2022 Q1 | -98.91 Thousand USD | -194.72% |
| 2022 Q3 | -77.69 Thousand USD | -0.16% |
| 2022 Q2 | -77.56 Thousand USD | 21.58% |
| 2022 Q4 | 25.2 Million USD | 32539.5% |
| 2021 FY | -313.46 Thousand USD | 70.34% |
| 2021 Q1 | -127.83 Thousand USD | -128.89% |
| 2021 Q3 | -71.05 Thousand USD | -7.36% |
| 2021 Q2 | -66.18 Thousand USD | 48.23% |
| 2021 Q4 | -33.56 Thousand USD | 52.76% |
| 2020 Q3 | -302.76 Thousand USD | 3.85% |
| 2020 Q4 | -55.85 Thousand USD | 81.55% |
| 2020 Q2 | -314.89 Thousand USD | 18.09% |
| 2020 FY | -1.05 Million USD | 61.13% |
| 2020 Q1 | -384.41 Thousand USD | 39.54% |
| 2019 Q3 | -678.54 Thousand USD | -7.25% |
| 2019 Q1 | -786.28 Thousand USD | 40.71% |
| 2019 FY | -2.71 Million USD | 40.25% |
| 2019 Q4 | -635.82 Thousand USD | 6.3% |
| 2019 Q2 | -632.69 Thousand USD | 19.53% |
| 2018 Q4 | -1.32 Million USD | -13.2% |
| 2018 FY | -4.55 Million USD | 10.8% |
| 2018 Q3 | -1.17 Million USD | -32.84% |
| 2018 Q2 | -881.91 Thousand USD | 24.66% |
| 2018 Q1 | -1.17 Million USD | -29.46% |
| 2017 Q4 | -904.21 Thousand USD | -33.15% |
| 2017 FY | -5.1 Million USD | 27.13% |
| 2017 Q1 | -2.8 Million USD | -1.81% |
| 2017 Q3 | -679.08 Thousand USD | 5.21% |
| 2017 Q2 | -716.44 Thousand USD | 74.43% |
| 2016 FY | -7 Million USD | -77.24% |
| 2016 Q4 | -2.75 Million USD | -59.52% |
| 2016 Q3 | -1.72 Million USD | -29.8% |
| 2016 Q2 | -1.32 Million USD | -11.26% |
| 2016 Q1 | -1.19 Million USD | -15.61% |
| 2015 Q2 | -791.65 Thousand USD | 14.2% |
| 2015 Q3 | -1.2 Million USD | -51.84% |
| 2015 Q4 | -1.03 Million USD | 14.05% |
| 2015 FY | -3.94 Million USD | 0.65% |
| 2015 Q1 | -922.67 Thousand USD | -2.74% |
| 2014 Q4 | -898.08 Thousand USD | -21.35% |
| 2014 Q2 | -2.14 Million USD | -989.46% |
| 2014 Q3 | -740.06 Thousand USD | 65.43% |
| 2014 FY | -3.97 Million USD | -116.63% |
| 2014 Q1 | -196.48 Thousand USD | 8.68% |
| 2013 Q3 | -1.29 Million USD | -384.23% |
| 2013 Q4 | -215.16 Thousand USD | 83.35% |
| 2013 Q2 | -266.9 Thousand USD | -340.84% |
| 2013 Q1 | -60.54 Thousand USD | 73.04% |
| 2013 FY | -1.83 Million USD | -1084.65% |
| 2012 Q4 | -224.58 Thousand USD | -135.08% |
| 2012 Q3 | 640.28 Thousand USD | 634.66% |
| 2012 Q2 | -119.75 Thousand USD | -9.29% |
| 2012 Q1 | -109.57 Thousand USD | 32.81% |
| 2012 FY | 186.36 Thousand USD | 181.78% |
| 2011 Q4 | -163.09 Thousand USD | -352.52% |
| 2011 Q3 | -36.04 Thousand USD | -169.57% |
| 2011 Q1 | -80.56 Thousand USD | 72.49% |
| 2011 Q2 | 51.8 Thousand USD | 164.31% |
| 2011 FY | -227.88 Thousand USD | 77.31% |
| 2010 Q1 | -255.05 Thousand USD | 28.15% |
| 2010 FY | -1 Million USD | 57.45% |
| 2010 Q4 | -292.85 Thousand USD | -23.0% |
| 2010 Q3 | -238.08 Thousand USD | -9.08% |
| 2010 Q2 | -218.27 Thousand USD | 14.42% |
| 2009 FY | -2.36 Million USD | 76.07% |
| 2009 Q4 | -354.96 Thousand USD | 43.94% |
| 2009 Q3 | -633.2 Thousand USD | -13.66% |
| 2009 Q2 | -557.1 Thousand USD | 31.65% |
| 2009 Q1 | -815.1 Thousand USD | 84.78% |
| 2008 FY | -9.86 Million USD | -257.59% |
| 2008 Q2 | -810.35 Thousand USD | 27.12% |
| 2008 Q1 | -1.11 Million USD | -774.75% |
| 2008 Q4 | -5.35 Million USD | -107.14% |
| 2008 Q3 | -2.58 Million USD | -219.02% |
| 2007 FY | -2.75 Million USD | -139.28% |
| 2007 Q3 | -1.62 Million USD | -1841.21% |
| 2007 Q2 | 93.48 Thousand USD | 123.39% |
| 2007 Q1 | -399.59 Thousand USD | 18.83% |
| 2007 Q4 | 164.79 Thousand USD | 110.12% |
| 2006 Q4 | -492.28 Thousand USD | -24.56% |
| 2006 Q3 | -395.21 Thousand USD | -934.92% |
| 2006 FY | -1.15 Million USD | -1556.78% |
| 2006 Q2 | -38.18 Thousand USD | 83.17% |
| 2006 Q1 | -226.96 Thousand USD | -733.42% |
| 2005 Q2 | 151.11 Thousand USD | 150.56% |
| 2005 Q1 | -298.89 Thousand USD | 47.35% |
| 2005 Q3 | 254.14 Thousand USD | 68.18% |
| 2005 Q4 | -27.23 Thousand USD | -110.72% |
| 2005 FY | 79.12 Thousand USD | 121.53% |
| 2004 Q1 | 73.6 Thousand USD | 452.65% |
| 2004 FY | -367.54 Thousand USD | -356.01% |
| 2004 Q3 | 104.43 Thousand USD | 372.85% |
| 2004 Q4 | -567.67 Thousand USD | -643.57% |
| 2004 Q2 | 22.08 Thousand USD | -70.0% |
| 2003 Q2 | -45.19 Thousand USD | 66.01% |
| 2003 Q1 | -132.96 Thousand USD | 66.2% |
| 2003 Q3 | 84.24 Thousand USD | 286.4% |
| 2003 FY | -80.6 Thousand USD | 87.12% |
| 2003 Q4 | 13.31 Thousand USD | -84.19% |
| 2002 FY | -625.72 Thousand USD | 62.6% |
| 2002 Q3 | 9604.00 USD | 106.58% |
| 2002 Q4 | -393.39 Thousand USD | -4196.11% |
| 2002 Q2 | -145.91 Thousand USD | -51.96% |
| 2002 Q1 | -96.02 Thousand USD | 85.28% |
| 2001 Q3 | -400.13 Thousand USD | -173.78% |
| 2001 Q1 | -474.49 Thousand USD | 23.77% |
| 2001 FY | -1.67 Million USD | -81.47% |
| 2001 Q4 | -652.24 Thousand USD | -63.01% |
| 2001 Q2 | -146.15 Thousand USD | 69.2% |
| 2000 FY | -921.91 Thousand USD | 55.91% |
| 2000 Q4 | -622.46 Thousand USD | -101.87% |
| 2000 Q3 | -308.35 Thousand USD | -355.04% |
| 2000 Q2 | -67.76 Thousand USD | -188.38% |
| 2000 Q1 | 76.67 Thousand USD | 115.61% |
| 1999 Q3 | -400 Thousand USD | 42.86% |
| 1999 FY | -2.09 Million USD | 0.42% |
| 1999 Q2 | -700 Thousand USD | -40.0% |
| 1999 Q4 | -491.19 Thousand USD | -22.8% |
| 1999 Q1 | -500 Thousand USD | 28.57% |
| 1998 Q3 | -500 Thousand USD | 16.67% |
| 1998 Q2 | -600 Thousand USD | -100.0% |
| 1998 Q1 | -300 Thousand USD | 50.0% |
| 1998 FY | -2.1 Million USD | -75.0% |
| 1998 Q4 | -700 Thousand USD | -40.0% |
| 1997 FY | -1.2 Million USD | -1300.0% |
| 1997 Q4 | -600 Thousand USD | 25.0% |
| 1997 Q3 | -800 Thousand USD | -1089.89% |
| 1997 Q1 | 80.81 Thousand USD | 0.0% |
| 1997 Q2 | 80.81 Thousand USD | 0.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -126.604% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 56.663% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 105.712% |
| Nascent Biotech, Inc. | -2.08 Million USD | -44.952% |
| Rebus Holdings, Inc. | -1.02 Million USD | -196.68% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 104.646% |
| Qrons Inc. | -789.34 Thousand USD | -283.372% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -378.511% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 95.166% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -628.348% |
| Skye Bioscience, Inc. | -37.64 Million USD | 91.961% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 95.963% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 53.983% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -1006.845% |
| SQZ Biotechnologies Company | -79.46 Million USD | 96.192% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -4.624% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -66.223% |
| Mesoblast Limited | -87.95 Million USD | 96.559% |
| Marizyme, Inc. | -65.34 Million USD | 95.369% |
| Genus plc | 7.9 Million USD | 138.306% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 72.216% |
| Pharming Group N.V. | -10.54 Million USD | 71.311% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -39.465% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 18.438% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 65.783% |
| ContraFect Corporation | -65.15 Million USD | 95.355% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 38.066% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -75.179% |
| IMV Inc. | -36.48 Million USD | 91.706% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 62.453% |
| MultiCell Technologies, Inc. | -380.07 USD | -796104.647% |
| ONE Bio Corp. | 8.67 Million USD | 134.877% |
| Accustem Sciences Inc. | -3.74 Million USD | 19.226% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 94.146% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -138.817% |
| Q BioMed Inc. | -2.05 Million USD | -47.466% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 18.936% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -27.102% |
| Biomind Labs Inc. | -1.21 Million USD | -149.204% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 94.933% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 2.438% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 61.709% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -55.246% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -20106.564% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 80.933% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 47.98% |
| GB Sciences, Inc. | -1.36 Million USD | -122.236% |
| Alpha Cognition Inc. | -13.77 Million USD | 78.028% |
| HST Global, Inc. | -146.21 Thousand USD | -1969.718% |
| CSL Limited | 2.64 Billion USD | 100.115% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -72.452% |
| Halberd Corporation | -79.67 Thousand USD | -3698.051% |
| Enzolytics Inc. | -2.17 Million USD | -39.016% |
| Agentix Corp. | -1.37 Million USD | -120.209% |
| Resverlogix Corp. | -3.61 Million USD | 16.174% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 4.582% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.974% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 3187.893% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 143.701% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 23.832% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | 52.817% |
| Zenith Capital Corp. | -10.59 Million USD | 71.441% |
| Genscript Biotech Corporation | -95.47 Million USD | 96.831% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -12920.114% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 27.01% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -4906.791% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -50.921% |
| Kadimastem Ltd | -3.3 Million USD | 8.504% |
| Helix BioMedix, Inc. | -1.05 Million USD | -186.55% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 20.761% |
| BioStem Technologies, Inc. | -8.48 Million USD | 64.327% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -585.625% |
| LadRx Corporation | 400.44 Thousand USD | 855.697% |
| Cell Source, Inc. | -5.32 Million USD | 43.131% |
| Regen BioPharma, Inc. | 1.02 Million USD | 395.663% |
| Regen BioPharma, Inc. | 1.02 Million USD | 395.663% |
| NovAccess Global Inc. | -4.76 Million USD | 36.548% |
| Affymax, Inc. | -14.42 Million USD | 79.02% |
| Itoco Inc. | -1.86 Million USD | -61.912% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 31.883% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -81.314% |
| Mobile Lads Corp. | -2.26 Million USD | -33.705% |
| CytoDyn Inc. | -49.84 Million USD | 93.928% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -3728.951% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -1226.513% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -221.406% |
| SYBLEU INC | -180.3 Thousand USD | -1578.352% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -87.64% |
| International Stem Cell Corporation | -131 Thousand USD | -2210.027% |
| Bioxytran, Inc. | -4.28 Million USD | 29.296% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -5475.868% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -19.598% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 93.705% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -43.147% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -287.525% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 4.478% |
| Neutra Corp. | -233.46 Thousand USD | -1196.184% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 85.086% |
| PureTech Health plc | -65.69 Million USD | 95.394% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 85.77% |
| IXICO plc | -1.17 Million USD | -156.888% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 69.516% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 94.703% |
| CSL Limited | 2.64 Billion USD | 100.115% |
| Cellectis S.A. | -103.17 Million USD | 97.067% |